$6.19▾ 2.83%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$3.08MTTM operating cash
Pre-profit
It generates operating cash even though it has no reported profit yet.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
-4.7%year over year
Weak
Revenue is contracting year over year.
Leverage
Highdebt to assets
Weak
High leverage relative to its assets.
More coming: dilution / share-count creep.
Fair value
Overvalued
Trading about 58% above our fair-value range
Value-trap risk
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Harvard Bioscience, Inc. is pre-profit. It generates operating cash even though it has no reported profit yet. Revenue is contracting year over year. High leverage relative to its assets.
Key numbers
Valuation
EPS (TTM)$-0.91
TTM (trailing 12 months, through fiscal Q1 FY2026)
Profitability
Net margin-11.4%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$85.53M
TTM (trailing 12 months, through fiscal Q1 FY2026)
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.